Bones are constantly changing—the body replaces its skeleton every 10 years
For generations, medicine has treated the skeleton as a structure to be preserved rather than restored — slowing its decay but rarely reversing it. Now, a team of researchers across three institutions has mapped more than 500 genes governing bone health, more than half of them previously unknown to science, revealing that the cells lining bone's blood vessels play a far greater role in skeletal repair than anyone had recognized. Drawing on genetic data from half a million people, the work published in Nature Genetics does not merely add to existing knowledge — it redraws the map of how living bone sustains itself, and opens the possibility that lost bone might one day be rebuilt rather than simply mourned.
- Nearly half of all adults over 50 live with osteoporosis, osteoarthritis, or related skeletal disease, yet most available treatments can only slow the damage — not undo it.
- A landmark genomic study of 500,000 individuals has identified more than 500 genes tied to bone health, shattering assumptions about which cells and pathways actually govern skeletal repair.
- Blood vessel cells surrounding bone — long treated as bystanders in skeletal research — have been revealed as active drivers of bone turnover, forcing a fundamental rethinking of how the field approaches treatment targets.
- The research team has released all data through an open-access platform, deliberately inviting the broader scientific community to accelerate the path from genetic map to viable drug candidates.
- Beyond bone disease, the findings point toward cancer: the same cellular mechanisms that rebuild bone may be harnessed to prevent dormant cancer cells from colonizing skeletal tissue during relapse.
Your skeleton is not the inert scaffold of anatomy class diagrams. It is living tissue, perpetually tearing itself down and rebuilding — replacing nearly its entire structure over the course of a decade. Until now, the genetic choreography behind that process remained largely unknown. A new study has changed that in ways that could fundamentally alter how bone disease is treated.
Researchers at UNSW's Garvan Institute, working with teams from Mater Research and Imperial College London, combined single-cell RNA sequencing with genetic data from half a million UK Biobank participants to map more than 500 genes involved in bone health. More than half had never previously been linked to skeletal biology. The study, published in Nature Genetics, identified 34 distinct cell types operating at the boundary between hard bone and bone marrow — the zone where formation and breakdown occur.
The most consequential surprise was the role of blood vessel cells. Long relegated to the periphery of bone research, these cells turned out to be significant drivers of repair and turnover. Lead researcher Ryan Chai described the scale of the discovery as a fundamental expansion of what medicine understands about the skeleton.
The stakes are considerable. Nearly half of adults over 50 live with osteoporosis, osteoarthritis, or related conditions. Current medications mostly slow bone loss rather than reverse it, leaving patients managing a gradual decline. The new genetic map suggests a different future — one where drugs might actively rebuild bone already lost. For Andrea Ulbrick, a Sydney woman diagnosed with severe osteoporosis at 44 and told her bones resembled those of a 70-year-old, that possibility represents something more than scientific progress.
The research also opens an unexpected window onto cancer. Bone is where dormant malignant cells hide and where many cancers relapse. Understanding the cellular mechanics of bone turnover may reveal ways to prevent cancer from establishing itself in skeletal tissue at all. The team has made its full dataset publicly available to hasten drug development, and the next phase will focus on translating this map into medicine — a timeline still uncertain, but now grounded in a far richer understanding of what bone actually is.
Your skeleton is not the fixed scaffold you learned about in school. It is living tissue, constantly dismantling itself and rebuilding—a process so thorough that your body replaces nearly its entire skeletal framework every decade. Until recently, scientists had only a fragmentary understanding of which cells orchestrate this perpetual renovation, and which genes direct the work. That gap has now closed in a way that could reshape how doctors treat bone disease.
Researchers led by Peter Croucher at UNSW's Garvan Institute, working alongside teams from Mater Research and Imperial College London, have mapped more than 500 genes involved in bone health—and more than half of them were previously unknown to play any role in skeletal regulation. The discovery emerged from combining single-cell RNA sequencing, which measures which genes are active inside individual cells, with genetic data from half a million people enrolled in the UK Biobank. The work, published in Nature Genetics, identified 34 distinct cell types operating at the interface between hard bone and bone marrow, the critical zone where bone forms and breaks down.
The most striking finding concerns blood vessel cells. Until now, these cells have occupied the margins of bone research, their contribution to skeletal health largely overlooked. The new mapping reveals them as significant drivers of bone repair and turnover—a reappraisal that opens entirely new avenues for therapeutic intervention. Ryan Chai, one of the study's lead researchers, emphasized the scale of the discovery: finding that more than half the identified genes had never before been linked to bone health represents a fundamental expansion of what medicine knows about skeletal biology.
The implications reach far beyond academic interest. Nearly half of all people over 50 live with some form of skeletal disease—osteoporosis, osteoarthritis, osteogenesis imperfecta, or rarer bone disorders. Most current medications work by slowing bone loss rather than reversing it, a limitation that leaves patients managing decline rather than recovery. The new genetic map offers a different possibility: drugs designed to target these newly discovered genes and cell types could actively rebuild bone that has already been lost.
Andrea Ulbrick, a Sydney woman diagnosed with severe osteoporosis at 44, learned her bones had the density of a 70-year-old's. The diagnosis was, by her own account, shocking and distressing. For patients like her, the research represents something beyond incremental progress—it suggests a future where treatment might mean restoration rather than mere stabilization.
The research also illuminates an unexpected connection to cancer. Bone is where dormant cancer cells hide, and where many cancers relapse. By understanding which cells and genes drive bone turnover, researchers have identified potential targets for preventing cancer from establishing itself in bone tissue. Croucher noted that the same cellular mechanisms that rebuild healthy bone can be exploited to stop malignant cells from taking root.
The team has made its data publicly available through an open-access platform, a decision intended to accelerate drug development across the research community. The next phase involves deeper investigation into how these newly identified genes and cells function in disease, with the goal of moving from mapping to medicine. For the millions living with weakened bones, the timeline from discovery to treatment remains uncertain. But the foundation has shifted. The skeleton, it turns out, holds more secrets than anyone realized—and now researchers have the tools to read them.
Citas Notables
Most of the drugs now available focus only on halting bone disease, rather than rebuilding lost bone, which is really important for reversing damage.— Peter Croucher, UNSW Garvan Institute
To think that this research could lead to the development of new treatments for osteoporosis is beyond my wildest dreams.— Andrea Ulbrick, osteoporosis patient
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that these genes were unknown until now? Didn't we already know how to treat bone disease?
We knew how to slow it down. But slowing a disease and reversing it are completely different problems. Most drugs available now are like putting a brake on bone loss—they don't rebuild what's already gone. These genes might let us do that.
And the blood vessel cells—why were they overlooked for so long?
Because researchers were focused on the obvious players: the cells that directly build bone and the cells that break it down. No one was looking carefully at the supporting cast. Blood vessels deliver nutrients, but it turns out they're doing something more active in bone repair than anyone appreciated.
The study used data from half a million people. How does that change what they could discover?
Scale matters enormously. With that many genomes, you can spot patterns that would be invisible in smaller studies. You can see which genetic variations actually affect bone density in real populations, not just in lab conditions.
One of the patients mentioned her bones were like a 70-year-old's at 44. Is that reversible?
That's the hope driving this research. Right now, no—we can slow the damage. But if these new genes can be targeted with drugs, theoretically yes. It would take years to develop and test, but the possibility is real.
You mentioned cancer. How does bone health connect to cancer spread?
Cancer cells often go dormant in bone, waiting. If we understand what makes bone cells active and what keeps them quiescent, we might be able to create an environment where cancer cells can't establish themselves. It's a secondary benefit, but potentially huge.
What happens next?
The researchers are investigating these genes more deeply, trying to understand exactly what each one does. Then comes the long process of drug development—finding molecules that can safely target these genes without harming healthy bone. It's not quick, but the map is now in place.